Blue Jay Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Blue Jay Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	$6.68M	Buy	+145,303	New	+$7.05M	4.55%	14
2016 Q4	–	Sell	-226,501	Closed	-$11.5M	–	20
2016 Q3	$11.5M	Sell	226,501 -79,129	-26%	-$3.94M	6.26%	9
2016 Q2	$13.9M	Sell	305,630 -50,880	-14%	-$2.34M	9.12%	1
2016 Q1	$14.1M	Buy	356,510 +156,450	+78%	+$6.21M	9.02%	3
2015 Q4	$11.3M	Buy	+200,060	New	+$10.2M	3.81%	15

Other funds holding NBIX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Blue Jay Capital Management's NBIX Position: Q2 2017 in Review

Blue Jay Capital Management opened a new position in Neurocrine Biosciences (NBIX) in Q2 2017: 145,303 shares worth $6.68M. The stake represents 4.55% of the portfolio and ranks #14 among its holdings. This is a return to the name: Blue Jay Capital Management previously reported a position in NBIX as recently as Q3 2016.

Blue Jay Capital Management first reported a position in NBIX in Q4 2015 and has held it in 5 quarters since. The position peaked at $14.1M in Q1 2016. 221 funds tracked by Wall St. Rank hold NBIX as of Q2 2017.

Blue Jay Capital Management held 145,303 shares of Neurocrine Biosciences worth $6.68M as of Q2 2017.
Neurocrine Biosciences was a new Blue Jay Capital Management position in Q2 2017.
Neurocrine Biosciences made up 4.55% of Blue Jay Capital Management's portfolio in Q2 2017, its #14 holding.
Blue Jay Capital Management first reported a position in Neurocrine Biosciences in Q4 2015 and has held it in 5 quarters since.
Blue Jay Capital Management's Neurocrine Biosciences position peaked at $14.1M in Q1 2016.
221 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2017.

Based on Blue Jay Capital Management's 13F filing for Q2 2017, filed 11 Aug 2017.